Skip to content

The TRICURE US IDE Pivotal Study

TRiCares Topaz Transcatheter Tricuspid Heart Valve Replacement System IDE Pivotal Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07528326
Acronym
TRICURE US IDE
Enrollment
831
Registered
2026-04-14
Start date
2026-10-01
Completion date
2035-09-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricuspid Regurgitation (TR)

Brief summary

The purpose of the study is to evaluate safety and effectiveness of the TRiCares Topaz TTVR system for treatment of subjects presenting with clinically relevant tricuspid regurgitation who are suitable for valve replacement.

Detailed description

The TRICURE US IDE Pivotal Study is a prospective, global, multi-center, randomized (1:1) controlled study (RCT) designed to evaluate the safety and effectiveness of the TRiCares Topaz TTVR System compared to the Edwards EVOQUE TTVR System in subjects with severe or greater tricuspid regurgitation.

Interventions

DEVICETRiCares Topaz TTVR System

TRiCares Topaz TTVR System

DEVICEEdwards EVOQUE TTVR System

Edwards EVOQUE TTVR System

Sponsors

TRiCares
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient is ≥ 18 years of age * Patient has severe or greater tricuspid regurgitation with symptoms despite optimal medical therapy * Patient is an appropriate candidate to undergo TTVR as determined by the Institution Heart Team

Exclusion criteria

* Patient has a tricuspid device currently in place * Patient has anatomical contraindications * Patient is in need of urgent surgery * Patient has a left ventricular ejection fraction of \< 25% * Patient has life expectancy of \< 1 year

Design outcomes

Primary

MeasureTime frameDescription
Rate of Major Adverse Events (MAE)30 days post-procedure
Composite Endpoint1 year post-procedureAll-cause mortality, heart failure hospitalization, non-elective tricuspid valve reintervention

Secondary

MeasureTime frameDescription
Change in qualify of life (QoL)1 year post-procedureas measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

Contacts

CONTACTStephanie Cihlar
cihlar@tricares.de763-227-7833
PRINCIPAL_INVESTIGATORPradeep Yadav, MD

Piedmont Hospital

PRINCIPAL_INVESTIGATORNeil Fam, MD

Unity Health Toronto

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026